Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25139958 | 0.81 | CA2 (0.37) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL22361547 | 0.81 | CA2 (0.39) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL1897437 | 0.80 | GPR84 (0.36) | GPR84FFAR1MAPT | |
| SCHEMBL24040220 | 0.79 | CA2 (0.41) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL531738 | 0.70 | CA2 (0.60) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL10884513 | 0.70 | CA2 (0.58) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL7095906 | 0.70 | — | — | |
| SCHEMBL2937529 | 0.68 | CA2 (0.58) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL7654397 | 0.68 | CA2 (0.58) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL7650538 | 0.68 | CA2 (0.58) | CA2MAPK1CA1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434970-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-20150252398-A1 | METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-09-10 | — | — | US | disclosed |
| US-9068207-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20140073018-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2 Tetrazolyl-Ethyl Ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2014-03-13 | — | — | US | disclosed |
| US-8404461-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK Biopharmaceutical Co. Ltd. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20110111467-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111467-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester | CES1, ADH1A, ADH1C | CA2 561/4885MAPK1 3423/4885CA1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.